A study to compare safety, pharmacokinetics and pharmacodynamics of AD-213-B to AD-2132 in healthy volunteers.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
40
Young-Ran Yoon
Daegu, South Korea
AUCtau
Evaluation PK after multiple dose
Time frame: From Day 1 up to Day 17
The change of Integrated gastric acidity(%) from baseline
Evaluation PD after multiple dose
Time frame: 4 times from Day -1 to Day 17
Cmax
Evaluation PK after single dose
Time frame: Day 1
AUClast
Evaluation PK after single dose
Time frame: Day 1
AUCinf
Evaluation PK after single dose
Time frame: Day 1
Tmax
Evaluation PK after single dose
Time frame: Day 1
t1/2
Evaluation PK after single dose
Time frame: Day 1
CL/F
Evaluation PK after single dose
Time frame: Day 1
Vd/F
Evaluation PK after single dose
Time frame: Day 1
Cmax,ss
Evaluation PK after multiple dose
Time frame: Day 1 up to Day 17
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Cmin,ss
Evaluation PK after multiple dose
Time frame: Day 1 up to Day 17
AUCinf
Evaluation PK after multiple dose
Time frame: Day 1 up to Day 17
Tmax,ss
Evaluation PK after multiple dose
Time frame: Day 1 up to Day 17
t1/2
Evaluation PK after multiple dose
Time frame: Day 1 up to Day 17
CLss/F
Evaluation PK after multiple dose
Time frame: Day 1 up to Day 17
Vdss/F
Evaluation PK after multiple dose
Time frame: Day 1 up to Day 17
The change of Integrated gastric acidity(mmol∙hr/L) from baseline
Evaluation PD after multiple dose
Time frame: 4 times from Day -1 to Day 17
Percentage of time to maintain gastric pH 4.0 or higher
Evaluation PD after multiple dose
Time frame: 4 times from Day -1 to Day 17